Bilirubin Metabolism, Jaundice, and Hyperbilirubinemia

1. Bilirubin Metabolism

Source of Bilirubin

• 70-80% derives from degradation of hemoglobin released from senescent erythrocytes (destroyed in the spleen, bone marrow, and liver Kupffer cells)
• 20-30% comes from breakdown of other heme-containing proteins (e.g., cytochrome oxidases, catalase) in hepatocytes, as well as ineffective erythropoiesis

Step 1: Heme to Bilirubin (in Peripheral Tissues)

1. Heme oxygenase (HO) opens the porphyrin ring of heme, releasing iron (Fe³+), carbon monoxide (CO), and producing biliverdin (a water-soluble green pigment). Two isoforms exist: HO-1 (inducible, ubiquitous) and HO-2 (constitutive, found in hepatocytes). The reaction requires NADPH and O₂.
2. Biliverdin reductase (BVRA) then reduces biliverdin IXα to bilirubin IXα (the predominant form), using NADPH.

Step 2: Transport in Blood

Step 3: Hepatic Handling - Four Key Steps

• Disrupts internal hydrogen bonds, making bilirubin highly water-soluble
• Is obligatory for biliary excretion

Step 4: Intestinal Metabolism and Enterohepatic Circulation

• Conjugated bilirubin passes down the gut without reabsorption by intestinal mucosa (which is relatively impermeable to it)
• Intestinal bacteria convert bilirubin to a series of colorless compounds called urobilinogens
• Most urobilinogen is excreted in feces (as stercobilin, giving stool its brown color)
• A small fraction is reabsorbed into the portal circulation and undergoes enterohepatic cycling - taken up again by the liver and re-excreted in bile; a small amount escapes hepatic extraction and enters systemic circulation to be excreted in urine as urobilinogen

Renal Excretion

• Unconjugated bilirubin is NOT excreted in urine - too tightly bound to albumin for glomerular filtration; no tubular secretion mechanism
• Conjugated bilirubin (water-soluble) is readily filtered at the glomerulus, hence bilirubinuria occurs in conjugated (direct) hyperbilirubinemia

2. Etiology and Pathogenesis of Jaundice

A. PRE-HEPATIC (Unconjugated Hyperbilirubinemia - Increased Production)

B. HEPATIC (Intrinsic Liver Disease)

i. Decreased Hepatic Uptake

• Gilbert syndrome (partial): Reduced uptake contributes to unconjugated hyperbilirubinemia
• Drugs: Rifampin, novobiocin, flavaspidic acid, cyclosporine, cholecystographic contrast agents inhibit OATP1B1 and bilirubin uptake

ii. Impaired Conjugation (Unconjugated Hyperbilirubinemia)

• Physiologic neonatal jaundice: UGT1A1 activity is low at birth; immature intestinal flora lead to enterohepatic circulation of unconjugated bilirubin. Usually resolves by 1-2 weeks.
• Gilbert syndrome: Mild reduction in UGT1A1 activity (due to promoter mutation - insertion in TATA box of UGT1A1 gene); unconjugated bilirubin typically <4 mg/dL; exacerbated by fasting, illness, exercise. Benign.
• Crigler-Najjar Syndrome Type I: Complete absence of UGT1A1 activity; bilirubin 20-45 mg/dL; risk of kernicterus; fatal without treatment (liver transplant).
• Crigler-Najjar Syndrome Type II: Severe reduction (not absence) of UGT1A1; bilirubin 6-25 mg/dL; responds to phenobarbital (induces residual enzyme); kernicterus rare.
• Breast milk jaundice: Prolonged mild unconjugated hyperbilirubinemia in neonates; possibly due to inhibitors of UGT1A1 in breast milk.

iii. Intrahepatic Excretion Defects (Conjugated/Direct Hyperbilirubinemia)

• Dubin-Johnson syndrome: Mutation in MRP2 (ABCC2); impaired canalicular export of conjugated bilirubin. Mild conjugated hyperbilirubinemia, black liver pigment on biopsy, elevated coproporphyrin isomer I in urine. Benign.
• Rotor syndrome: Mutations in both OATP1B1 and OATP1B3; impaired sinusoidal re-uptake of refluxed conjugated bilirubin. Mild conjugated hyperbilirubinemia. Benign.
• Benign recurrent intrahepatic cholestasis (BRIC): Mutations in FIC1 (ATP8B1) or BSEP (ABCB11); recurrent episodes of cholestasis.
• Progressive familial intrahepatic cholestasis (PFIC): Same gene defects as BRIC but more severe; can progress to liver failure.

iv. Hepatocellular Disease (Mixed/Conjugated Hyperbilirubinemia)

• Acute viral hepatitis (HAV, HBV, HCV, HDV, HEV): Hepatocellular necrosis and inflammation → impaired all steps of bilirubin metabolism. Preceded by prodrome of malaise, anorexia, myalgias.
• Drug-induced liver injury (DILI): Acetaminophen (dose-dependent), idiosyncratic drug reactions
• Alcoholic hepatitis: Multifactorial liver injury
• Ischemic hepatitis: Hypotension, hypoxia, hyperthermia, Budd-Chiari syndrome
• Wilson disease: Inherited disorder of copper metabolism; may mimic acute viral hepatitis; hemolytic component adds unconjugated bilirubin
• Chronic liver disease/Cirrhosis: Viral hepatitis (B, C), NAFLD/NASH, alcoholic cirrhosis, hemochromatosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis - jaundice generally signals advanced disease
• Drugs producing intrahepatic cholestasis: Estrogens (down-regulate NTCP, inhibit BSEP and MRP2), anabolic steroids, total parenteral nutrition
• Sepsis-associated cholestasis: Cytokine-mediated down-regulation of NTCP, MRP2, and BSEP
• Paraneoplastic (Stauffer syndrome): Intrahepatic cholestasis without hepatic infiltration, especially renal cell carcinoma and lymphoma; resolves with tumor treatment

C. POST-HEPATIC (Obstructive/Cholestatic) - Conjugated Hyperbilirubinemia

3. Direct vs. Indirect Hyperbilirubinemia

• Direct-reacting bilirubin = conjugated bilirubin (water-soluble; reacts directly without alcohol addition)
• Indirect-reacting bilirubin = unconjugated bilirubin (lipid-soluble; requires alcohol addition to react)
• Total bilirubin = direct + indirect

Key Clinical Distinction

• If direct bilirubin >50% of total: implies hepatocellular disease or biliary obstruction - requires further workup (liver enzymes, imaging)
• If indirect bilirubin predominates: think pre-hepatic (hemolysis) or impaired conjugation
• The direct fraction as measured by clinical labs is typically ≤15% of total in pure hemolysis (Harrison's, Chap. 349)
• Conjugated bilirubin can be filtered and excreted in urine; unconjugated cannot - hence the clinical pearl: "acholuric jaundice" (jaundice without bilirubinuria) = unconjugated hyperbilirubinemia (e.g., hemolysis)

Bilirubin Metabolism

Phase 1 - Bilirubin Production (Peripheral Tissues)

Sources of Bilirubin

Enzymatic Conversion: Heme → Biliverdin → Bilirubin

• Opens the porphyrin ring of heme at the α-methene bridge
• Reaction requires NADPH and O₂
• Produces biliverdin (a water-soluble green pigment), releases Fe³+ (recycled for new hemoglobin) and CO (transported as carboxyhemoglobin - a useful marker of hemolytic rate)
• Two isoforms: HO-1 (inducible, ubiquitous, localized to endoplasmic reticulum) and HO-2 (constitutive, expressed selectively in hepatocytes and brain, localized to mitochondria)

• Reduces biliverdin IXα to bilirubin IXα (the predominant adult form)
• Reaction requires NADPH (NADPH → NADP⁺)
• BVRA is a ubiquitously expressed cell surface membrane protein

Phase 2 - Plasma Transport

• Keeps it soluble in plasma
• Prevents its entry into tissues (especially brain) and excretion in urine
• Allows efficient delivery to the liver

Phase 3 - Hepatic Uptake

1. Passive diffusion - free bilirubin can flip across the membrane
2. Carrier-mediated transport - via members of the organic anion transporting polypeptide (OATP) family (particularly OATP1B1 and OATP1B3), which are 12-transmembrane-domain glycoproteins. The exact transporter responsible for unconjugated bilirubin uptake remains debated; competitive inhibition by rifampin and cyclosporine A (which inhibit OATP1B1) provides indirect evidence for a carrier.

• Keep bilirubin in solution (prevent precipitation)
• Prevent its back-diffusion out of the cell
• Shuttle it to the smooth endoplasmic reticulum (SER) by diffusion

Phase 4 - Conjugation

Bilirubin + 2 UDP-glucuronic acid (UDPGA) → Bilirubin diglucuronide + 2 UDP

• Bilirubin diglucuronide (BDG) - predominant form (~80% in bile)
• Bilirubin monoglucuronide (BMG) - minor form (~20% in bile)
• Small amounts of triglucuronide also form
• Note: The ratio of monoconjugated to diconjugated is ~1:4 in bile, but nearly 1:1 in plasma (monoglucuronides reflux into plasma more readily)

• Disrupts the internal hydrogen bonds of unconjugated bilirubin
• Converts a lipid-soluble, water-insoluble compound into a highly water-soluble one
• Conjugation is obligatory for excretion into bile

The UGT1 Gene Complex

• Contains at least 13 substrate-specific first exons (A1, A2 ... A13), each with its own promoter, encoding the amino-terminal ~286 amino acids (substrate-binding domain) of different isoforms
• 4 shared common exons (2-5) encode the carboxyl-terminal half (UDP-glucuronic acid binding site + transmembrane domain)
• Four first exons are pseudogenes; nine functional UGT1 isoforms are expressed

Phase 5 - Biliary Excretion

• MRP2 (Multidrug Resistance-associated Protein 2, ABCC2) - an ATP-dependent export pump on the canalicular membrane. This is the primary route. Mutations in MRP2 cause Dubin-Johnson syndrome.
• A portion of glucuronides is also exported back into the portal circulation via MRP3 (ABCC3) on the sinusoidal membrane, then undergoes re-uptake into hepatocytes via OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3). Loss-of-function mutations in both OATP1B1 and OATP1B3 cause Rotor syndrome (impaired re-uptake of refluxed conjugated bilirubin).

Phase 6 - Intestinal Metabolism and Enterohepatic Circulation

• The intestinal mucosa is relatively impermeable to conjugated bilirubin - it is NOT absorbed in the small intestine
• In the colon, intestinal bacteria deconjugate and enzymatically reduce bilirubin to a series of colorless compounds collectively called urobilinogens (including mesobilinogen, stercobilinogen)
• Most urobilinogen (~80%) is oxidized and excreted in feces as stercobilin - this gives stool its characteristic brown color

Enterohepatic Circulation of Urobilinogen

• A fraction of urobilinogen (~20%) is reabsorbed from the colon into the portal circulation
• The liver re-extracts and re-excretes the majority back into bile (enterohepatic circulation)
• A small amount escapes hepatic extraction, enters systemic circulation, and is filtered by the kidneys and excreted in urine as urobilinogen

Note: Unconjugated bilirubin does NOT normally reach the gut in adults. It only does so in neonates or in severe unconjugated hyperbilirubinemia (e.g., Crigler-Najjar Type I). If it reaches the gut, it can be partly reabsorbed, amplifying the hyperbilirubinemia.

Renal Excretion - Summary

Delta Bilirubin (δ-Bilirubin) - Clinically Important

Summary Flowchart

HEME (from senescent RBCs, hemoproteins)
        ↓  Heme oxygenase (NADPH + O₂ → CO + Fe³⁺ + NADP⁺)
    BILIVERDIN (water-soluble, green)
        ↓  Biliverdin reductase (NADPH → NADP⁺)
UNCONJUGATED BILIRUBIN (lipid-soluble, yellow-orange)
        ↓  Bound to albumin in plasma
    LIVER HEPATOCYTE
        ↓  Uptake via OATP/diffusion; bound to GST (ligandin)
    SMOOTH ER → UGT1A1 conjugation with UDP-glucuronic acid
        ↓
CONJUGATED BILIRUBIN (water-soluble diglucuronide)
        ↓  MRP2 (ATP-dependent) → Bile canaliculus
    BILE DUCTS → DUODENUM → INTESTINE
        ↓  Bacterial action
    UROBILINOGEN
    ↙           ↘
Excreted in feces    Reabsorbed → Portal vein
(stercobilin-brown)      ↙           ↘
                  Re-excreted    Urine urobilinogen
                  in bile

Normal Serum Bilirubin Values

Etiology and Pathogenesis of Jaundice

Classification Framework

JAUNDICE
│
├── I. PRE-HEPATIC
│       └── Increased bilirubin production
│              → Unconjugated (indirect) hyperbilirubinemia
│
├── II. HEPATIC (Intra-hepatic)
│       ├── A. Decreased hepatic uptake
│       ├── B. Impaired conjugation         → Unconjugated hyperbilirubinemia
│       ├── C. Impaired canalicular excretion
│       └── D. Hepatocellular disease       → Mixed/conjugated hyperbilirubinemia
│
└── III. POST-HEPATIC
        └── Biliary obstruction             → Conjugated (direct) hyperbilirubinemia

I. PRE-HEPATIC JAUNDICE

Key point: Even with complete hemolysis, the bone marrow can sustain at most an 8-fold increase in RBC production. Thus, hemolysis alone cannot sustain serum bilirubin above ~4 mg/dL in a liver with normal function. Higher levels imply concurrent hepatic dysfunction.

1. Hemolysis (Most Common Pre-hepatic Cause)

• Accelerated RBC destruction → massive release of hemoglobin → heme catabolism exceeds hepatic conjugating capacity → accumulation of unconjugated bilirubin
• Bilirubin remains unconjugated; direct fraction ≤15% of total
• Prolonged hemolysis → precipitation of bilirubin salts in the biliary tree → pigment (bilirubin) gallstones → secondary obstructive jaundice

2. Ineffective Erythropoiesis

• Developing erythroid cells are destroyed within the bone marrow before entering circulation
• Normally only a small fraction of bilirubin comes from intramedullary destruction; in these disorders it can reach up to 70% of total bilirubin production
• Results in modest unconjugated hyperbilirubinemia

3. Resorption of Hematoma / Tissue Infarction

4. Massive Blood Transfusion

5. Hypoalbuminemia (Defective Transport)

II. HEPATIC (INTRAHEPATIC) JAUNDICE

A. Decreased Hepatic Uptake → Unconjugated Hyperbilirubinemia

B. Impaired Conjugation → Unconjugated Hyperbilirubinemia

(i) Physiologic Neonatal Jaundice

• Fetal bilirubin was cleared by the placenta and maternal liver
• At birth, the neonatal liver suddenly assumes responsibility for clearance
• UGT1A1 activity is low at birth (immature)
• Intestinal flora that convert bilirubin to urobilinogen are also undeveloped
• Alternative excretory pathways allow passage of unconjugated bilirubin into the gut, where it is reabsorbed (enterohepatic circulation of unconjugated bilirubin)
• Result: Nearly all neonates develop mild unconjugated hyperbilirubinemia in the first week of life; typically resolves by 1-2 weeks

(ii) Gilbert Syndrome

• Mild reduction in bilirubin conjugation + decreased hepatic uptake
• Serum bilirubin typically <4 mg/dL (usually unconjugated)
• Exacerbated by fasting, physical stress, illness, intercurrent infections, alcohol
• Entirely benign; no liver damage

(iii) Crigler-Najjar Syndrome, Type I (CN-I)

• Total absence of bilirubin conjugation
• Bilirubin diglucuronide is virtually absent from bile
• Serum unconjugated bilirubin: 20-45 mg/dL (340-765 µmol/L)
• Bilirubin eliminated only by alternative pathways: direct passage into bile and small intestine as bilirubin photoisomers
• No response to phenobarbital (no residual enzyme to induce)
• Unconjugated bilirubin crosses the blood-brain barrier → kernicterus (bilirubin encephalopathy) - usual outcome without treatment
• Fatal without liver transplantation

(iv) Crigler-Najjar Syndrome, Type II (CN-II)

• Serum unconjugated bilirubin: 6-25 mg/dL (usually <20 mg/dL)
• Small amount of bilirubin glucuronide present in bile (predominantly monoglucuronide)
• Responds to phenobarbital (induces residual enzyme) - serum bilirubin falls >25%
• Kernicterus rare (occurs mainly with physiologic stress, illness, fasting)
• Long-term prognosis better than CN-I; some patients managed with phenobarbital + phototherapy

(v) Breast Milk Jaundice

(vi) Acquired Conjugation Defects

C. Impaired Canalicular Excretion of Conjugated Bilirubin → Conjugated Hyperbilirubinemia

(i) Dubin-Johnson Syndrome (DJS)

• Conjugated bilirubin formed normally but cannot be exported into the bile canaliculus
• Refluxes back into plasma → conjugated hyperbilirubinemia + bilirubinuria
• Serum bilirubin typically 2-5 mg/dL (predominantly conjugated); occasionally higher
• Liver appears grossly black due to accumulation of dark melanin-like pigment in hepatocytes (lysosomal)
• Diagnostic hallmark: urinary coproporphyrin isomer I ≥80% of total (normally ~25%)
• Otherwise completely benign; normal liver function tests (ALP, transaminases); normal life expectancy

(ii) Rotor Syndrome (RS)

• These transporters normally mediate sinusoidal re-uptake of conjugated bilirubin that has refluxed from the hepatocyte into the portal circulation
• Loss of both → conjugated bilirubin cannot be recaptured → accumulates in plasma
• Mild conjugated hyperbilirubinemia; bilirubinuria present
• Liver has no abnormal pigmentation (unlike DJS)
• Total urinary coproporphyrin is substantially increased (distinguishes from DJS); gallbladder usually visualized on oral cholecystography (opposite of DJS)
• Benign, normal life expectancy

(iii) Benign Recurrent Intrahepatic Cholestasis (BRIC) and Progressive Familial Intrahepatic Cholestasis (PFIC)

D. Hepatocellular Disease → Mixed (Unconjugated + Conjugated) Hyperbilirubinemia

(i) Acute Hepatocellular Disease

(ii) Intrahepatic Cholestasis (Drug/Hormone-Induced)

(iii) Chronic Hepatocellular Disease / Cirrhosis

• Chronic viral hepatitis B and C
• Alcoholic cirrhosis (ARLD)
• Non-alcoholic fatty liver disease (NAFLD/NASH) → NASH cirrhosis
• Hemochromatosis (HFE gene mutations; decades of iron overload)
• Alpha-1-antitrypsin deficiency (misfolded ZZ-phenotype protein accumulates in hepatocyte ER)
• Wilson disease (copper accumulation → progressive fibrosis)
• Autoimmune hepatitis

(iv) Paraneoplastic (Stauffer Syndrome)

III. POST-HEPATIC (OBSTRUCTIVE / CHOLESTATIC) JAUNDICE

Intraluminal Obstruction (Within the Bile Duct Lumen)

• Choledocholithiasis (common bile duct stones) - most common cause; stone may originate from gallbladder or form de novo in the duct; often complicates prolonged hemolysis (pigment stones)
• Biliary parasites (Clonorchis sinensis, Ascaris lumbricoides)
• Blood clots (hemobilia)

Mural Obstruction (Wall of Bile Duct)

• Cholangiocarcinoma (Klatskin tumor at the hilum; intrahepatic; distal CBD)
• Primary sclerosing cholangitis (PSC) - autoimmune fibro-inflammatory stricturing of intra- and extrahepatic bile ducts; strongly associated with ulcerative colitis
• Benign biliary strictures - post-operative (surgical clips, ischemic injury), post-inflammatory
• Cholangitis (acute bacterial cholangitis - infection superimposed on obstruction)
• Biliary atresia (neonates - fibro-obliterative process of bile ducts; presents as neonatal cholestatic jaundice)
• Caroli disease (congenital dilation of intrahepatic bile ducts)

Extramural Compression (External Compression of Bile Duct)

• Carcinoma of head of pancreas - most common malignant cause of obstructive jaundice; compresses distal CBD → painless progressive jaundice (Courvoisier's sign)
• Ampullary carcinoma - jaundice + often GI bleeding
• Chronic pancreatitis - fibrotic stricture of the intrapancreatic CBD
• Pancreatic pseudocyst - external compression
• Mirizzi syndrome - large gallstone in the cystic duct compresses the common hepatic duct
• Lymphadenopathy at the porta hepatis - metastatic nodes (gastric, colorectal, breast cancer)
• Retroperitoneal fibrosis

Surgical Complications

• Misplaced surgical clips, retained stones, inadvertent ischemic injury to biliary system during cholecystectomy or hepatobiliary surgery → obstructive jaundice (may present immediately or years later)

Summary Table: Key Features by Mechanism